Vanda Pharmaceuticals Inc.'s agreement to license a portfolio of preclinical cystic fibrosis transmembrane conductance regulator (CFTR) modulators from the University of California, San Francisco (UCSF) is not an attempt to compete with Vertex Pharmaceuticals Inc. and others in cystic fibrosis – but an effort to get a head start in other therapeutic areas where this class of therapeutics may play a role.
Vanda's Licenses CFTR Modulators From UCSF, But Not For Cystic Fibrosis
Intellectual property licensed from UCSF focuses on non-mutated, wild-type CFTR activators and inhibitors, thought to offer potential in ophthalmic, renal and gastrointestinal indications.
More from Business
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
More from Scrip
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.